Home > What We Do > Participate in a Clinical Trial

Australian Alzheimer’s Research FOUNDATION is currently seeking participants for the following trials:

Study NAME AND WHO IS ELIGIBLE
THE SCHEDULE

Australian Alzheimer’s Research Foundation – TotAL Study Phase 2

This study aims to evaluate the impact of testosterone alone or in combination with fish oil on amyloid load in the brain, as well as whether it affects performance on tests of memory, cognition and function.

Who can be involved:

  • Males aged 60 to 80 years of age inclusive, at the time of informed consent
  • Have memory concerns
  • Does not have a current medical or neurological condition
  • Not currently taking testosterone or diagnosed with hypogonadism

For further information please contact Shane Fernandez, Study Coordinator on Ph: 08 6304 3957 or Email: s.fernandez@ecu.edu.au or Helen Daniels, Unit Manager on 08 6304 3966 or Email: h.daniels@ecu.edu.au

What is involved:

  • 18 month duration
  • Most visits 8 weeks apart
  • Testosterone/placebo will be administered intramuscularly every 8 weeks and fish oil/placebo taken orally every day
  • Medical examinations, memory tests, brain scans, and cerebrospinal fluid collection

AbbVie – AWARE STUDY Phase 2

The Aware study is evaluating an investigational medication (ABBV-8E12) that targets protein called tau, which builds-up in the brains of people with Early Alzheimer’s disease. This study will help determine if the investigational medication is safe and effective at slowing the progression of Early Alzheimer’s disease.

Who can be involved:

  • Male or female and age is between 55 and 85 years, at the time of informed consent
  • Must be diagnosed with mild cognitive impairment or mild Alzheimer’s disease
  • Has an identified, reliable, study partner (e.g. family member)
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 12 weeks prior to randomization

 

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved

  • Monthly visits for intravenous infusions of the medication.
  • 22 months duration

 

ACTINOGEN MEDICAL – XanADu Phase 2

This study will assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease. Xanamem has been developed in response to evidence that there is a strong association between chronically raised cortisol levels in the blood and in the brain, and the development of Alzheimer’s disease.

Who can be involved:

  • Male or female, aged 50 to 85 years old inclusive, at the time of informed consent
  • Has an identified, reliable, study partner (e.g., family member)
  • Must be diagnosed with mild Alzheimer’s disease 
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 12 weeks prior to randomization

 

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved:

  • Monthly visits
  • Daily medication  (tablets)
  • 20 weeks duration

EISAI Co.,Ltd. – Mission AD Phase 3

To evaluate the efficacy and safety of elenbecestat (E2609) on participant’s with early Alzheimer’s disease (including mild cognitive impairment due to Alzheimer’s and a subset of very mild Alzheimer’s disease dementia).

Who can be involved:

  • Male or female, aged 50 to 85 years old inclusive, at the time of informed consent
  • Has an identified, reliable, study partner (who spends 8+ hours a week with the subject)
  • Must have mild cognitive impairment due to Alzheimer’s disease or diagnosed with Alzheimer’s disease

 

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved:

  • Monthly – quarterly visits
  • Daily medication  (tablets)
  • 29 months duration

Avanir Pharmaceuticals – AVP-786 Phase 3

To evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimer’s type.

Who can be involved:

  • Male or female, aged 50 to 90 years of age inclusive, at the time of informed consent
  • Has an identified, reliable, study partner willing to participate.
  • Clinically significant moderate-sever agitation as defined by the IPA consensus definition of agitation in cognitive disorders
  • Must have a diagnosis of probable Alzheimer’s disease

 

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved:

  • Fortnightly visits
  • Twice daily medication (tablets)
  • 16 weeks duration

Hoffmann-La Roche – GRADuate Phase 3

This study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with prodromal Alzheimer’s Disease.

Who can be involved:

  • Male or female, aged 50 to 90 years of age inclusive, at the time of informed consent
  • Has an identified, reliable, study partner (who spends 10+ hours a week with the subject)
  • Must have mild cognitive impairment due to Alzheimer’s disease or diagnosed with Alzheimer’s dementia

 

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved:

  • Monthly visits
  • Monthly medication (subcutaneous injection)
  • 28 month duration

Novartis Pharmaceuticals – Generation Phase 2/3

To test whether two investigational drugs called CAD106 and CNP250, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer’s disease in participants at risk to develop clinical symptoms based on their age and genotype.

Who can be involved:

  • Male or female, aged 60 to 75 years of age inclusive, at the time of informed consent
  • Does not have a current medical or neurological condition that might impact cognition or performance on cognitive assessments
  • Has an identified, reliable, study partner

 

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

What is involved:

  • 4 visits per year
  • 12 month duration for genetic disclosure then 3-5 year study duration
  • Medication will be administered intramuscularly or orally depending on the cohort

 

* Please note that participants in all studies may have a chance of being placed on a placebo medication